eGenesis Revenue and Competitors
Estimated Revenue & Valuation
- eGenesis's estimated annual revenue is currently $18.3M per year.
- eGenesis's estimated revenue per employee is $155,000
- eGenesis's total funding is $265M.
Employee Data
- eGenesis has 118 Employees.
- eGenesis grew their employee count by -3% last year.
eGenesis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director Immunology and Translational Sciences | Reveal Email/Phone |
2 | Sr. Director, Business Development and Alliance Management | Reveal Email/Phone |
3 | Senior Administrative Assistant | Reveal Email/Phone |
4 | Head Intellectual Property | Reveal Email/Phone |
5 | Strategic Advisor | Reveal Email/Phone |
6 | Associate Director | Reveal Email/Phone |
7 | Chief Technology Officer | Reveal Email/Phone |
8 | Scientist | Reveal Email/Phone |
9 | Director, Synthetic Biology | Reveal Email/Phone |
10 | Director, Regulatory Affairs CMC | Reveal Email/Phone |
eGenesis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is eGenesis?
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.
keywords:N/A
$265M
Total Funding
118
Number of Employees
$18.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
eGenesis News
When Michael Curtis joined xenotransplantation startup eGenesis as president of R&D in late-2020, he knew he'd one day become CEO.
Katz is an ideal fit for eGenesis because of both his clinical experience as a transplant surgeon and his successful career in the...
Xenotransplant gene editor eGenesis snags transplant expert as CMO; John Tsai, Susanne Schaffert among the hard cuts made at Novartis · Endpoints 20 under 40;...
eGenesis, a Cambridge, Mass.-based gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, completed a $125m Series C financing. Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, Lif ...
eGenesis, a Cambridge, Mass.-based biotechnology company utilizing gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, completed a $100m Series B financing. The round was led by Fresenius Medical Care Ventures (FMCV), ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 118 | 24% | $16.7M |
#2 | $38.1M | 118 | 7% | N/A |
#3 | $23.7M | 118 | 42% | $25M |
#4 | $18.3M | 118 | 23% | N/A |
#5 | $24.3M | 119 | 5% | N/A |